Parameter
| Biomarker | AFP (alpha-fetoprotein) | Full name | Alpha-fetoprotein | Molecular Type | Protein |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Diagnosis, prognosis, prediction | ||
| Disease | Gastric Cancer | Disease Subtypes | / | ||
| Organ | Stomach | Test Sample / Technology Platform | Serum (ELISA, chemiluminescence immunoassay), tumor tissue (IHC) | ||
| Pathobiological Mechanisms | Normally synthesized by fetal liver cells, gastric cancer cells (especially hepatoid adenocarcinoma subtypes) re-express due to cell dedifferentiation, and promote tumor proliferation, invasion and liver metastasis by activating PI3K/Akt pathway. Patients with high expression of PI3K/ AKT have poor response to chemotherapy and short survival time | ||||
| Clinical Availability Status | Clinical use (subtype diagnosis/prognosis evaluation) : It is used for the diagnosis and prognosis of a special subtype of gastric cancer (hepatoid adenocarcinoma), and is not the first choice in routine gastric cancer detection | ||||
| Notes and Dynamics | It has specific diagnostic value for hepatoid adenocarcinoma and yolk sac tumor-like subtype of gastric cancer, and can predict the risk of liver metastasis. Patients with high AFP level should be preferentially screened for liver metastasis. It is a key marker for gastric cancer subtype and individualized treatment | ||||